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Abstract
Medicaid, Medicare, and major insurance companies are being faced with increased costs for
drug test screening. These costs are not caused by a spike in the use of narcotics by subscribers,
but from unnecessary testing and overbilling by doctors and drug screening companies.
Recovering drug addicts are required to have random drug tests during their treatment program,
but instead of being random, the drug tests have become prescriptive. Testing is performed at
specific times weekly on a single patient, for substances that return results that are unimportant
to the doctors. Doctors are given drug testing kits by large drug testing companies that are very
accurate and low in cost. Once the necessary drug tests are completed, the insurance companies
are billed for thousands of dollars. The test results are received by the doctors who are able to
confirm or deny the use of a particular drug. Next, the doctors send the exact test sample to a
drug testing company or laboratory for further confirmatory testing. Medicaid, Medicare, and
employers are billed twice by way of the insurance companies, for the same tests on a single
patient on the same date of service; first from the doctor and then from the laboratory (The
Pathology Blawg). My focus will be to examine the current drug test billing system, assess the
risks and vulnerabilities faced by Medicare, Medicaid and the insurance companies and analyze
and recommend strategies to detect and eliminate fraud, waste and abuse (FWA) caused from
healthcare provider billing schemes.
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The History of Fraud, Waste and Abuse
David Friedrichs in his book Trusted Criminals: White Collar Crime in Contemporary
Society, states that medical facilities have defrauded the government of billions of dollars
annually through federally funded healthcare programs. Frederichs also stated that in 1995 FBI
Director Louis Freeh contented that health care fraud was the fastest growing crime in the United
States. The federal government confirmed “that medical fraud accounted for between 3 and 10
percent of the annual $1 trillion U.S. health care bill.” Taxpayers have been left to foot a
significant portion of this tax bill (Fredrichs).
Fraud is “knowingly and willingly executing, or attempting to execute, a scheme to defraud a
health care benefit program.” Fraud is committed when money or property is obtained by means
of false or fraudulent pretenses, promises or representations from organizations that administer
health care benefit programs.
Waste involves the over use of services or practices that result in unnecessary costs to the health
care system. Waste is the misuse of resources; the actions of waste is not considered criminally
negligent.
Abuse includes any action that directly or indirectly results in unnecessary costs to the health
care system. Incorrect payments are made for services not rendered or which did not meet
professional standards. Healthcare providers and suppliers may unknowingly receive payments
for which they are not legally entitled. This stems from the intentional misrepresentation of facts
from subscribers, and thus makes abuse not easily identifiable. What constitutes “abuse” or
“fraud” depends on specific facts and circumstances such as intent, prior knowledge, and
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available evidence (Addressing Fraud, Waste and Abuse).
The Impact of Fraud, Waste and Abuse on the Healthcare Industry
Fraudulent claims are a big burden to the insurance industry. In 2011, The National
Health Care Anti-Fraud Association (NHCAA) reported that “$2.27 trillion was spent on health
care and more than four billion health insurance claims were processed in the United States.”
The fraudulent claims among these processed claims are of a small percentage, yet the cost to the
government is huge (NHCAA).
The Centers for Medicare and Medicaid Services (CMS) anticipated total health care
expenditures to reach $2.4 trillion in 2008. With the effects of demographics and the rising cost
of medical treatment, total health care spending was projected to reach $4.14 trillion by the year
2018. This amount accounts for a large amount of the gross domestic product. In 2007, the
National Health Care Anti-Fraud Association estimated that health care fraud accounted for three
percent or $68 billion of health care expenditure in the United States. For that same year, the
Federal Bureau of Investigation (FBI) expected losses due to health care fraud was between three
and ten percent; at ten percent the losses would reach $226 billion (Price).
The FBI reports that health care fraud is a rising threat that costs the country tens of
billions of dollars a year. National health care expenditures were estimated to exceed $3 trillion
in 2014 with spending outperforming inflation (Health Care Fraud). These CMS statistics tells us
that fraud has a devastating financial impact on health care organizations. An analysis done by
the ACL Services Ltd., an audit and risk management transformation company, found that not
only does fraud affect a company financially, but operationally and psychologically as well.
Operationally, fraud disrupts the continuous work cycle of a company and psychologically,
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employees become distrusting of each other and the providers and subscribers they serve. While
the monetary loss is substantial, the full impact of fraud on an organization is overwhelming as
these losses demoralize a company’s reputation, goodwill, and customer relations. An effective
fraud management program is a guaranteed deterrent that will protect healthcare organization’s
assets and reputation (Coderre).
Fraudulent activities can be perpetrated by any employee within an organization or by
external affiliates. As the NHCAA states, whether subscribers have an employer-sponsored or a
self-funded insurance plan, health care fraud unavoidably translates into higher premiums and
out-of-pocket expenses as well as reduced benefits or coverage. For both private and government
employers, health care fraud increases the cost of providing insurance benefits for employees and
the overall cost of doing business. This increased expense is an added burden, especially to
households with minimal residual income, and will force many Americans to make the decision
as to whether or not health insurance is purchased for their households (NHCAA).
A September 2009 article in the Journal of the American Academy of Psychiatry and the
Law, indicated that health care fraud is not a victimless crime. Health care companies will
attempt to recoup sustained losses and all costs associated with this are passed on to the
subscribers. The diversion of funds due to fraud increases the costs of providing legitimate
medical services, while decreasing an organization’s net income. Providers will institute
mechanisms designed to recoup these losses and these mechanisms will sometimes include
unethical practices. Health insurance companies may reduce benefit coverage while self-funded
individuals will pay higher premiums. The federal government may change eligibility
requirements for programs such as Medicaid, and employers may request higher copays from
their employees. Physicians may compromise patient safety and perform unnecessary procedures
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and will bill for services never rendered. A false medical history is created and patients may later
sustain difficulties obtaining disability or life insurance policies. An inaccurate medical history
influences treatment decisions, and some insurance companies may deny coverage to subscribers
based on a medical condition that does not exist. The medical profession is one of the most
ethical professions in the United States; health care fraud tarnishes this reputation and raises
questions about the ethics governing the profession as a whole (Price).
Provider Healthcare Fraud
The NHCAA indicates that the majority of health care fraud is committed by a small
minority of dishonest health care providers. Fraudulent providers take advantage of the
confidence entrusted to them by their patients. The actions of these providers destroy the
reputation of perhaps the most trusted and respected physicians in our society. Physicians have
access to patients’ records and a wide range of medical conditions and treatments with which to
perpetrate a fraud scheme. Unlimited access to medical codes and patients who need constant
treatment, gives the provider the ability to submit false claims for numerous insurers.
Distributing false or fraudulent claims among insurers sponsored by public programs such as
Medicare and Medicaid, increases fraud proceeds while lessening the chances of these providers
being detected.
According to the NHCAA, dishonest providers commit fraud by:
•

Billing for services that were never rendered. Genuine patient information may be
obtained through identity theft to fabricate entire claims or legitimate claims are padded
with charges for procedures or services that did not occur.
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•

Upcoding thus billing for more expensive services or procedures than were actually
provided or performed. Providers will inflate a patient’s diagnosis to a more serious
condition and falsely bill insurers for a substantially higher-priced treatment than was
actually provided. Performing medically unnecessary services solely for the purpose of
generating insurance payments is often seen in fraudulent nerve-conduction and other
diagnostic-testing claims.

•

Non-covered treatments are misrepresented as medically necessary and covered for the
purposes of obtaining insurance payments. In cases such as cosmetic-surgery schemes,
non-covered cosmetic procedures such as nose jobs are billed to patients' insurers as
deviated-septum repairs.

•

Unbundling - each step of a procedure is billed as if it was a separate procedure. This is
seen in the treatment of drug addicts when drug tests from a single blood sample that
detect a variety of narcotics is separated into multiple tests and billed separately.

•

Patients are billed for more than, or for the co-pay amounts for services that are paid in
full by the benefit plan.

•

Providers may accept kickbacks from treatment facilities or hospitals for patient referrals.

•

Providers may waive patient co-pays or deductibles for medical or dental care and overbill the insurance companies. Policies set by insurers with regard to co-pay waivers are
ignored by providers, thus violating the contracting process. Medicare prohibits routinely
waiving co-pays unless it’s due to financial hardship (NHCAA).
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The Concept of Drug Screening and Confirmatory Tests
According to the Substance Abuse and Mental Health Services Administration
(SAMSHA), an agency of the U.S. Department of Health and Human Services, drug testing is
typically a two-step process involving an initial drug screen done to identify possibly positive
and negative specimens. A confirmatory test follows the initial screening to analyze any positive
specimen detected. Screening tests, also known as initial tests, indicate the presence or absence
of a specific substance or one that is chemically similar. These are qualitative analyses that
confirm if the drug is absent or present in a particular specimen. Blood, urine and saliva are the
most common specimens. Screening tests done in a laboratory or onsite in a physician’s office,
are referred to as point-of-care tests (POCT). These tests are inexpensive, easily automated, and
produce immediate results. Technological advances have led to improvements in confirmatory
tests, giving laboratories the option to bypass screening tests and use confirmatory tests for
specimen analysis (USDHHS).
Medicare Fraud in Drug Test Screening
The Wall Street Journal reports that medical providers are cashing in on costly drug tests
that are unnecessary and billing Medicare for these costs. Doctors are conducting unnecessary
drug tests on seniors for opiates such as heroin, cocaine and angel dust which few use. These
tests are totally unnecessary and Medicare is billed for these test costs. Doctors are encouraged to
operate by medical guidelines when treating patients, especially for pain, and test these patients
to make sure they are neither abusing pills nor failing to take them. Unscrupulous pain doctors
are making more from testing patients than from treating them.
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Medicare became aware of abusive practices being carried out during simple urine tests
and changed its billing procedures. Some doctors moved on to high-tech testing methods, where
billing wasn’t limited and started testing for a variety of different drugs. Medicare or Medicaid,
the federal health program for the elderly and disabled, is billed separately for each substance. In
the Wall Street Journal report, the writer states that one provider who owns a laboratory and does
high-tech tests for physicians, believes that testing for a broad range of drugs makes sense. Hightech tests are more accurate than single tests. These tests lessens the risk of missing substanceabusers. Medicare spent $445 million on 22 high-tech tests for drugs of abuse in 2012, and $14
million for angel dust or PCP testing; this amount increased 1,423% in five years (Weaver).
Case Study 1
Calloway Laboratories
In April 2012, Calloway Laboratories of Woburn, Massachusetts agreed to pay $20
million dollars to the state to settle charges that it defrauded Medicaid out of millions of dollars
through an elaborate kickback scheme involving sham companies, fake doctor signatures, and
excessive urine testing for impoverished drug addicts. Two executives of Calloway Laboratories,
chief executive officer Arthur Levitan and chief operating officer Patrick Cavanaugh, as well as
two employees of sober homes (group homes for recovering drug addicts) were indicted by a
grand jury on charges involving the creation of straw companies. These straw companies were
used to funnel bribes to the managers of sober homes, and in return for these bribes, the
managers allegedly required tenants to undergo excessive urine screening. The lab work was sent
to Calloway Laboratories and paid for by Medicaid. Much of the lab work was not ordered by a
doctor or authorized medical provider as required by law, and claim documents included falsified
doctors’ signatures (Wen).
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Arthur Levitan and Patrick Cavanaugh along with William Maragioglio, an associate who
owned and operated a sober home, were sentenced to four years of probation for a kickback
scheme that cost the state Medicaid program millions of dollars (Conaboy). Under the settlement
made by Calloway Laboratories, Arthur Levitan and Patrick Cavanaugh were no longer
employed by or allowed to consult for Calloway Laboratories. The company agreed to a threeyear compliance and monitoring program by the state of Massachusetts (Wen).
In May 2014, Calloway Laboratories again settled a lawsuit with the state of West
Virginia for false billings submitted to West Virginia Medicaid and nationwide to Medicare. The
investigation was conducted by the West Virginia Medicaid Fraud Control Unit (WV MFCU)
and the United States Department of Health and Human Services, Office of the Inspector
General (HHS-OIG). It was found that from March 2009 to April 2013, Calloway Labs billed
Medicare and West Virginia Medicaid for false drug tests by using a pathology services code, in
addition to the required code for urine drug testing. Calloway Labs performed a medical review
with every urine drug screen, but billed Medicare and Medicaid for pathology services that were
never rendered. Medical reviews are not covered by Medicare or West Virginia Medicaid but
Calloway Labs submitted these claims under false pretenses and collected payments. A new
management team brought on in 2012 by Calloway Labs’ new owners voluntarily discarded the
company’s fraudulent billing practices (Justice News).
Sober Homes
Sober homes is an informal term used for rental homes marketed to recovering substance
abusers. These homes are low-budget rooms found in apartment buildings or houses, usually in
recession-plagued neighborhoods. Recovering addicts are guaranteed a safe environment which
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assisted each individual with the resources necessary for recovery. Residents had to adhere to
mandatory urine tests which are performed about three times weekly to uphold the zero-tolerance
rule for substance abuse. Even with these stringent rules, addicts or tenants got high and were
amazed to find out they were not penalized when the tests results came up positive. Contrary the
house rules, the residents were not evicted by their landlords, but instead were used to keep the
drug testing scheme afloat .The recovering addicts were the money-makers for the sober homes
and private drug-testing labs. This was a little-known niche of the drug testing world. Landlords
needed the labs so they could prove their seriousness about sobriety, and largely to get referrals
so the rooms of the sober homes will be continually filled. On the other hand, the labs needed
access to numerous deprived substance abusers whose drug-screening tests qualified for lucrative
Medicaid reimbursements that are worth millions of dollars annually (Wen).
During a 2011 investigation by the Attorney General of Massachusetts, it was found that
the owners of sober omes were accepting bribes from a renowned Massachusetts doctor,
Punyamurtula Kishore. Dr. Kishore was arrested for falsely billing the State of Massachusetts $4
million in Medicaid reimbursements (Wen). The sober homes involved, required the recovering
addicts housed in their facilities to submit to urine drug screens at least three times weekly.
These urine tests had to be performed by the physician office laboratories owned by Dr. Kishore
at a cost of approximately $100 to $200 per test (Karpinsky). (Appendix D gives the link to the
author, Patricia Wen’s account of her recorded interview with Dr. Punyamurtula Kishore and his
involvement of sober homes.)
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Case Study 2
Preventive Medicine Associates
Dr. Kishore is the founder of Preventive Medicine Associates. Dr. Kishore owned and
operated 29 treatment facilities throughout the state of Massachusetts, where each clinic
specialized in opiate addiction treatment using a medication called Vivitrol. Patients suffering
from opiate addiction were conventionally treated with methadone or Suboxone therapy.
However, Dr. Kishore claimed that Vivitrol was a safer non-addictive form of treatment (Wen).
In 2011, Dr. Kishore and Preventative Medical Associates were indicted and each charged with
eight counts of Medicaid Kickbacks, eleven counts of larceny and eight counts of Medicaid False
Claims to sober homes. The investigation was conducted by the Attorney General of
Massachusetts and in 2013 additional charges of eleven counts of Medicaid False Claims and
eleven counts of larceny were added to the original counts (Fennimore). New Horizon House is a
sober home situated in a Quincy, Massachusetts. The home had strict rules against relapsing and
required all residents to use Dr. Kishore, or one of his associates, as their primary care doctor.
Recovering addicts were scheduled to submit three urine samples each week, with each test
performed at Preventive Medicine Associates. Urine testing is typically paid for by Medicaid
with remuneration ranging between $100 to $200 for each urine screen, as long as a doctor signs
a form stating the test is medically necessary (Wen).
Dr. Kishore’s approach to sobriety is known as The Massachusetts Model. This regimen
of drug testing differed from what many top addiction specialists, including John F. Kelly of the
Center for Addiction Medicine at Massachusetts General Hospital, recommend for most
recovering addicts in sober home settings. Normal procedures used to prove if a substance abuser
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has relapsed is doing random drug testing unbeknownst to the addict; not scheduled weekly
testing as conducted by Dr. Kishore’s facilities. Dr. Kishore’s sales pitches to sober homes
emphasized the fact that he was a medical doctor, and employed other doctors who could
properly authorize drug tests. Dr. Kishore distributed literature that promoted his labs and
compared his clinics to other commercial labs. The literature claims that commercial labs
“Performs testing, then asks for referral after the fact (illegal),” while his labs “require a
complete physical, obtain a complete patient history, then order and perform testing (legal).” Dr.
Kishore began attracting more business from sober home managers as he was seen as a dedicated
doctor willing to focus on substance abusers (Wen).
“Precision Testing Laboratories”, a competing laboratory, filed a lawsuit claiming
Dr. Kishore’s labs stole a number of its sober home clients including New Horizon. Precision’s
lawyers subpoenaed Dr. Kishore’s bank records and found about a dozen $1,000 checks paid to
New Horizon House for “facility fees.” These payments were viewed as bribes, even though they
were veiled as salaries for no-show jobs and fees for alleged bed rentals or space in sober homes.
Some of these checks were drawn on an account in the name of a nonprofit institution known as
the National Library of Addictions. Dr. Kishore created this institution as an educational
resource for drug treatment specialists. In all, the case involved more than 860 Medicaid
recipients with more than 53,000 claims. Dr. Kishore and Preventive Medicine Associates pled
not guilty and defended the payments to the sober homes as legitimate business expenses (Wen).
In April 2015, Dr. Kishore pled guilty to all counts of his indictment and will serve 11
months in jail with a ten year suspended sentence. In addition, Dr. Kishore and Preventative
Medical Associates will pay $9.3 million in restitution for operating a Medicaid fraud scheme.
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Dr. Kishore agreed to surrender his medical license (Fennimore). (Appendix B shows the
revenue stream for the companies in both case studies.)
Oversight and Internal Controls for Drug Screening Claims in the State of Massachusetts
The Medicaid program in the state of Massachussets, known as MassHealth, is
administered by the Executive Office of Health and Human Services (EOHHS). Between July 1,
2008 and June 30, 2011, the Office of the State Auditor conducted an audit of MassHealth due to
increased fraudulent activity against Medicaid; especially the frauds committed by Preventative
Medicine Associates and Dr. Punyamurtula Kishore. MassHealth was developed to provide
yearly access to healthcare services for low and mid income families. MassHealth’s upsurge in
healthcare costs are due particularly to claims for drug test billing, as since 2007 MassHealth’s
expenditures have risen annually on average by 8.69%. According to the Official Audit Report,
in 2011 MassHealth paid healthcare providers more than $11.1 billion. An estimated 40% of this
expenditure was funded by the state.
MassHealth’s services include providing drug tests for subscribers with substance abuse
disorders. Payments are made to physicians who directly order and authorize drug tests or to
members who are being actively treated. MassHealth established internal controls over the
payment process for laboratory drug tests, to ensure payments are made only for medically
necessary drug tests claims. The objective of this audit on MassHealth was to ascertain:


If drug testing claims paid by MassHealth were medically necessary for subscribers
with substance abuse disorders.



If required documentations were submitted to substantiate these claims.
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Whether the services being billed were actually provided.



If the billing and payment process conformed to the Massachusetts’ state laws and
MassHealth’s policies.



If cost savings incentives and strategies were utilized.

The audit on MassHealth generated the following findings:
•

MassHealth paid for drug tests allocated to members on a daily basis for extended
periods, sometimes surpassing a year. This process deviated from the guidelines
recommended by the federal Substance Abuse and Mental Health Services
Administration (SAMHSA), and those of other substance abuse treatment professionals.
It was found that MassHealth could have saved approximately $7.8 million if the State’s
policies and procedures were adhered to.

•

Three laboratories were audited and it was discovered that “unbundling” was used when
billing for drug testing services. Unbundling occurs when a group of drug testing
procedure codes are billed separately. Contrary to Federal and State laws, this group of
procedures must be billed using an all-inclusive procedure code. For four fiscal years
ending June 30, 2012, unbundling costs to the State of Massachusetts totaled
approximately $4.5 million.

•

A glitch in MassHealth’s claims processing system prevented claims for duplicate drug
tests from being denied. Currently healthcare providers are permitted to test members
with substance abuse disorders once daily. Approximately $286,000 was expended for
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15,606 instances where MassHealth paid for claims submitted for the same member on
the same day.
•

Pricing changes for drug tests approved by the state were not effectively implemented by
MassHealth. On February 1, 2009, MassHealth had a price reduction in standard
multiclass drug tests, but these pricing adjustments were not implemented until 9 days
later, causing overpayments of $107,309 on 2,348 claims.

•

Documentation requirements instituted by MassHealth were not followed by the
laboratories when submitting drug test claims. Laboratory order forms and test results
were unavailable at two of the three laboratories where the audit testing was conducted.
However, the laboratories were paid $41,258 for these services. Physician’s
authorizations and diagnosis codes were missing, a breach of MassHealth’s policies.
MassHealth’s 30-day testing period limit was violated as standing order forms were used
for periods surpassing this limit. Instances were found where testing was done with
incomplete or sometimes non-existent forms (Official Audit Report).

Recommendations for Increased Oversight
The losses incurred by MassHealth could have been avoided if its management had
actively enforced its policies: seeing to it that the frequency with which members received drug
tests were monitored, investigated providers who submitted unusually large numbers of claims
for drug tests per member, and ensured that tests that were originated by physicians were for
medically necessary purposes for the member that was actively being treated.
The State Auditor recommended that MassHealth implement simple processes to detect
deficiencies in its system to improve claims processing. It was suggested that system edits,
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programs designed to detect flaws in medical claim processing software, be developed to
successfully prevent fraudulent claims for drug tests ordered during the residential monitoring of
substance abuse patients. Claims submitted frequently for a particular member would be detected
during processing, analyzed, and verified for adherence to state policies. In order to track the
payment of claims for any member, it was recommended that proper identification of the
provider be submitted. This includes the physician’s or treatment facility’s name, identification
number, and the diagnosis code used for treatment.
All claim information is housed in MassHealth’s data warehouse. Irregularities such as
high-frequency drug testing would be easily identified which could improve the quality of claims
processed within the Medicaid Management Information System (MMIS). If MassHealth
develops new requirements such as specific drug testing codes and patient identification
numbers, it would be impossible for laboratories to continually test a single subscriber and
submit unnecessary claims. MassHealth would then be in line with state and federal standards
governing the use of drug screening services.
The Official Audit Report states that MassHealth should “monitor the frequency with
which members receive drug tests and investigate providers who submit unusually large numbers
of claims.” Constant monitoring by MassHealth will ensure that drug tests are done only when
medically necessary, and are ordered by physicians who are actively treating members with
substance abuse disorders. System edits for unnecessary laboratory tests will be developed to
establish regulations, detect and disallow claims for same day drug screens and confirmatory
drug tests.
MassHealth will frequently review the system edits programmed in its claims processing
software, to ensure that claims which violate state regulations will be readily identified.
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Facilitating communication between MassHealth and healthcare or laboratory providers can
alleviate all misunderstandings of how payments are processed for state provided services.
Providers will be notified of duplicate verification tests and will be advised if these procedures
are covered. The Office of the State Auditor recommended that Provider Bulletins outlining
requirements for requesting laboratory services and recordkeeping be issued to laboratory
providers (See Appendix F, 130 CMR 401.416 to 401.417, 410.455 to 410.459) (Official Audit
Report).
The recommendations given to MassHealth by the Massachusetts Office of the State
auditor can be successfully applied not only to state administered insurance plans, but to
insurance companies that administer state and employer funded plans. Having effective internal
controls such as implementing system edits will prevent, detect and reduce any fraudulent claims
submitted by a provider. Adding a data mining software to a claims processing system will
monitor incoming claims, and reveal subscribers who have a large volume of drug test claims,
over the amount considered normal for a specific period.
Healthcare Fraud and Abuse Laws
The Anti-Kickback Statute
Jennifer Staman’s article in the Congressional Research Service states that the
government was concerned that profit was a major influence for health care providers. Statues
had to be enacted to protect federal healthcare programs from being financially violated. The
anti-kickback statute was passed by Congress, making it a felony for anyone to deliberately
profit or generate business from a federal health care program. Payments from a these programs
derived from exploiting residents of sober homes or substance abusers is forbidden. Persons
found guilty for arranging scheduled drug tests contrary to state or federal policies will be in
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violation of the anti-kickback statute. Violators will be subject to imprisonment of up to five
years or fined up to $25,000. Healthcare providers or drug testing laboratories will receive up to
a one year suspension from participating in all federal health care programs (Staman).
The False Claims Act
The Federal False Claims Act (FCA) has been used to fight fraud against the U.S.
government, recovering more than $12.1 billion within a four year span, from January 2009 to
the June 2013 fiscal year. The FCA is used when prosecuting health care fraud cases and the
Justice Department has imposed civil liabilities on providers, who knowingly submit false or
fraudulent claims from billing services. These include services not provided, needless medical
services, double billing or upcoding. Healthcare providers and laboratories will be fined a
maximum of $11,000 per false claim filed and all additional damages incurred (Staman).
Policies Instituted by Insurance Companies
Two prominent insurance companies, AmeriHealth Caritas and Independence Blue Cross
(IBC) are contracted by the government to provide cost-effective healthcare solutions for
publicly-funded programs, such as Medicaid. On the company’s website, AmeriHealth Caritas
states “it has made health care fraud prevention and detection a primary emphasis,” with an
increased focus on preventing improper payments. Health care fraud is reduced when a
prevention and detection fraud system is implemented instead of a pay and chase method of
recovery for improper payments. Numerous processes are in place, all designed to prevent and
detect fraud, waste, and abuse. These include:
Preventive actions
Multiple front-end system edit codes are used to detect recurring claims for specific subscribers
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or drug testing providers. Claim alerts are initiated for high-dollar claims prior to disbursement.
A pre-distribution review will ascertain the legitimacy of a submitted claim and authorizations
must be received from subscribers or employers before payments are made to providers.
Post-payment actions
Medical claim data checks are done to analyze the frequency with which providers submit claims
or use specific billing codes. Payment trend analysis is used to detect the frequency with which
payments are made to providers.
Corporate and Financial Investigations (CFI)
Anti-fraud software is installed on claims processing systems to identify fraud, waste and abuse
patterns. The detection of these patterns will allow the analysis of claims data to help identify
improper payments. Pharmacy audits are conducted to see how often claims for high dollar drugs
are made by any particular pharmacy (Fraud, Waste and Abuse).
IBC has specific policies on presumptive and definitive drug testing. IBC’s decisions for
coverage and payment of claims are based on the Centers for Medicare and Medicaid Services
(CMS) regulations and guidelines. Presumptive drug tests are performed as baseline screenings
and are done before or during a treatment process. Definitive drug tests are confirmatory tests
ordered for verification if a presumptive test is positive. Providers have been successful in
receiving fraudulent payments by double-billing insurance companies for negative presumptive
drug tests and definitive tests on the same specimen. This is an unnecessary process as a negative
presumptive test cannot result in a positive definitive test. IBC has implemented policies to
eliminate double-billing by providers (IBC).
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Presumptive Drug Testing
Payment for presumptive drug tests are based on standards implemented for individuals
receiving treatment for pain management or substance abuse. Presumptive drug testing is
considered medically necessary, covered and paid for by IBC when an initial testing is
conducted, during the treatment process, when an assessment of the member’s medical history is
performed and treatment for substance abuse is found to be medically necessary.
Definitive Drug Testing
Definitive drug testing is conducted when it is ordered by a treating provider or when the
presumptive test results are positive. The definitive testing is also conducted when a presumptive
test result is negative and this finding is inconsistent with the individual’s medical history (IBC).
Drug treatment facilities test residents via a single screen for up to 15 substances which cost
$100 per screen. If the test returns positive for a specific drug, the 15 samples are sent for further
confirmatory or definitive tests as individual samples. The insurance company will be billed
$100 for the first single screen containing 15 samples, and then $1,500.00 for the 15 individual
confirmatory tests (Lynne). This constitutes both fraud and waste as definitive tests are required
only for positive preliminary test results.
Covered Claims
IBC policies state that drug testing is considered medically necessary and the company will
cover 16 claims per calendar year. Consideration will be given to members who are believed to
be continuing a pattern of substance abuse, and coverage will be extended beyond the 16 claim
maximum.
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Unnecessary Drug Tests
Providers will submit claims for routine presumptive or definitive drug tests, whereby members
are tested at every visit. Double testing is done by testing for the same drug with both a blood
and a urine specimen at the same time. This is unnecessary and IBC has instituted system edits to
detect multiple presumptive or definitive drug tests for members, and have also limited these
tests to 120 times in a calendar year. (IBC).
Conclusion
Medicaid, Medicare and major insurance companies are being faced with increased costs
for drug test screening. These costs are not caused by a spike in the use of narcotics by
subscribers, but from unnecessary testing and overbilling by doctors and drug screening
companies. The government is a major player in the healthcare industry as they are the principal
payers of insurance claims and are susceptible to fraud. Employers who self-fund their
employees’ insurance premiums are also vulnerable and have become joint victims to
perpetrating providers. The healthcare industry needs to focus on prevention in order to eliminate
fraud, waste and abuse in medical claim billing. Keeping ahead of technological advances is an
effective way of reducing over billing in the industry. Diagnosis coding has been the weak link
through which most fraud schemes have been perpetrated. These codes need to be updated
regularly in accordance with nationally accepted coding guidelines, especially when new
procedures have been implemented due to technological advances. This policy needs to be
applied to all future applicable coding changes, revisions, or updates.
Having effective internal controls over billing procedures is a deterrent and thus limits
the chances providers may take to overbill the insurance company or the government.
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Recovering drug addicts are required to have random drug tests during or as a part of their
treatment program, but instead of being random, the drug tests have become precise. Testing is
performed at specific times weekly on a single patient, for substances that return results that are
unimportant to the doctors. If a weakness is found in a billing procedure, precautions should be
taken to immediately change the billing structure or policies governing the structure. An open
forum needs to be developed that gives providers a means of discussing any issue associated
with the costs of administering drug tests.
Doctors are given drug testing kits by large drug testing companies that are very accurate
and low in cost. Once the necessary drug tests are completed, the insurance companies are billed
for thousands of dollars. The test results are received by the doctors and they are able to confirm
or deny the use of a particular drug. This exact test sample is then and there sent to a drug testing
company or laboratory for further confirmatory testing. Medicaid, Medicare, and self-funding
employers are billed twice by way of the insurance companies, for the same tests on a single
patient on the same date of service; first from the doctor and then from the laboratory.
Medical claims from providers should be routinely checked to ensure that the proper
codes are being used for patients, and all providers made aware of changes to the policies and
procedures of an insurance company or the CMS. The use of data mining software is an effective
tool for conducting analysis, and identifying specific patterns in claim submission from providers
that may indicate fraud (The Pathology Blawg).
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Appendix A
Abbreviations and Terminology
CMS – Centers for Medicare and Medicaid Services

DMA – Division of Medical Assistance

EOHHS – Executive Office of Health and Human Services

FBI – Federal Bureau of Investigation

FWA – Fraud, Waste and Abuse

IBC – Independence Blue Cross
NHCAA – National Health Care Anti-Fraud Association
MassHealth – Office of Medicaid

MMIS – Medicaid Management Information System

POCT – Point-of-Care Test

SAMSHA – Substance Abuse and Mental Health Services Administration
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HHS-OIG – United States Department of Health and Human Services, Office of the Inspector
General
USDHHS – U.S. Dept. of Health and Human Services
WV MFCU – West Virginia Medicaid Fraud Control Unit
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Appendix B

Source: http://www.bostonglobe.com/metro/2012/03/31/seeking-help-but-finding-scam-soberhomes/qmOkEiD4ZaUJ1Vf3NyZ8oJ/igraphic.html?p1=Article_Graphic
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Appendix C

Source: http://www.wsj.com/articles/doctors-cash-in-on-drug-tests-for-seniors-and-medicarepays-the-bill-1415676782
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Appendix D
Boston Globe reporter Patricia Wen, gives a precise explanation how sober homes use drug
addicts to fund their lucrative fraud scheme. Ms. Wen interviewed Dr. Punyamurtula Kishore,
the founder of Preventive Medicine Associates, and owner/operator of 29 treatment facilities
throughout the state of Massachusetts. Dr. Kishore was arrested and charged with eight counts of
Medicaid fraud, 12 counts of larceny and with eight counts of illegal kickbacks to housing
programs, known as sober homes, for recovering addicts. Ms. Wen interviewed Dr. Kishore at
one of his offices. Her account of the interview can be seen here:
Link: http://www.bostonglobe.com/metro/2012/03/31/seeking-help-but-finding-scam-soberhomes/qmOkEiD4ZaUJ1Vf3NyZ8oJ/video.html?p1=Article_Video_More
Source: Boston Globe, April 1, 2012.
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Appendix E
Preventive Medical Care – The Massachusetts Model
The Chalcedon claims that Dr. Punyamurtula Kishore is arguably the twenty-first century's
greatest pioneer in the treatment of substance addiction. Dr. Kishore developed
the Massachusetts Model program which is characterized by a thorough and ongoing medical

assessment of drug abuse patients and of multimodal therapeutic approaches. It may include full
and comprehensive physical examinations, laboratory testing, toxicology, cardiac, neurological
and pulmonary evaluations, education and support, and other methods. This program was
claimed to far out-perform the existing treatment paradigms at vastly lower costs. The link below
shows Dr. Kishore explaining his approach on rehabilitating drug addicts:
Link: https://www.youtube.com/watch?v=OVE0hB-SI9c

Sources: http://punyamurtulakishore.org/massachusetts-model.html
http://chalcedon.edu/research/articles/massachusetts-protects-medical-industrial-
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Appendix F

130 CMR: DIVISION OF MEDICAL ASSISTANCE

401.416: Request for Laboratory Services
(A) Request Requirements. The independent clinical laboratory may not bill for a service
unless it has received a written request to perform that specific service from an authorized
prescriber who is treating the member and will use the test for the purpose of diagnosis,
treatment, or an otherwise medically necessary reason as defined in 130 CMR 450.204. Any
independent clinical laboratory billing for a service must maintain such request in its records,
and
make such records available to the MassHealth agency and the Attorney General's Medicaid
Fraud Division upon request. If the laboratory that billed for the service cannot produce the
original request, the MassHealth agency may deny or recover payment for all services the
laboratory provided based on that request.
(B) Standing Orders. An authorized prescriber may request an independent clinical laboratory
to perform one or more tests on a single date, or issue a standing order for such tests. Standing
order requests may not exceed 180 days in length with the exception of standing order requests
for substance abuse testing, which may not exceed 30 days in length. Standing order requests are
not permissible unless such repeated tests are medically necessary and required as part of the
member's medical or drug treatment plan.
(C) Required Information. Requests for laboratory services must be written and include the
following information:
(1) the date of the request;
(2) the name or any other means of identifying the member to be tested;
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(3) the name and address of the authorized prescriber (if the authorized prescriber is a
Massachusetts Department of Public Health licensed substance abuse treatment program for
the sole purpose allowed pursuant to 130 CMR 401.402, the request must include the names
and addresses of both the substance abuse treatment program and the physician initiating the
request);
(4) the name of the specific laboratory tests to be performed;
(5) the frequency for performing each laboratory test (applicable to standing orders only);
(6) the duration and maximum number of times each laboratory test or tests are to be
performed (applicable to standing orders only); and
(7) a statement by the authorized prescriber that such testing is required as part of the
member's medical or drug treatment plan (applicable to standing orders only).
(D) Recordkeeping. If a laboratory refers a specimen to a testing laboratory, the referring
laboratory must forward the original request to perform the service to the testing laboratory. The
testing laboratory must maintain such request in its records in accordance with 130 CMR
401.416(A).

401.417: Recordkeeping Requirements
Both referring and testing laboratories must keep a record of each written request for
laboratory services, each specimen, and each test result for at least six years from the date on
which the results were reported to the authorized prescriber. If the testing laboratory is a
subsidiary-related entity of the referring laboratory, such records may be maintained at one
location, but must be made available to the MassHealth agency and the Attorney General’s
Medicaid Fraud Division upon request, in accordance with 130 CMR 450.205. If an independent
clinical laboratory cannot produce the record to substantiate a MassHealth claim, the MassHealth
agency may deny or recover payment for that claim. The laboratory record must contain the
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following information:
(A) The written request for laboratory services with all information required by 130 CMR
401.416;
(B) the identification number of the specimen;
(C) the name or any other means of identifying the person from whom the specimen was taken;
(D) the name of the authorized prescriber and, if applicable, the referring laboratory that
submitted the specimen.
(E) the date on which the specimen was collected by the authorized prescriber or laboratory,
the location of the collection, and the name of the collector;
(F) the date on which the specimen was received in the laboratory;
(G) the condition of unsatisfactory specimens when received (for example, broken, leaked,
hemolyzed, or turbid);
(H) the specific tests performed;
(I) the date or dates on which each test was performed;
(J) the results of each test, the name and address of all persons to whom each test result is
reported, and the date of reporting; and
(K) the name and address of the laboratory to which the specimen was referred, if applicable.

410.455: Laboratory Services: Introduction
(A) 130 CMR 410.455 through 410.459 establish the requirements and procedures for clinical
laboratory services provided by hospital outpatient departments. A clinical laboratory service
includes the following types of services: microbiological, serological, chemistry, hematological,
radioimmunoassay, cytological, immunological, pathological, or other examinations of materials
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derived from the human body to provide information for the assessment of a medical condition
or for the diagnosis, prevention, or treatment of any disease.
(B) The MassHealth agency does not pay separately for routine specimen collection and
preparation for the purpose of clinical laboratory analysis (for example, venipuncture; urine,
fecal, and sputum samples; Pap smears; cultures; and swabbing and scraping for removal of
tissue.) Specimen collection and preparation is considered part of the laboratory service.
410.456: Laboratory Services: Payment
(A) Maximum Allowable Fee. The maximum allowable payment for an acute or nonacute
hospital outpatient department or hospital-licensed health center laboratory service is the lowest
of the following:
(1) the amount in effect for the date of service in the DHCFP Clinical Laboratory Services fee
schedule at 114.3 CMR 20.00 and 114.3 CMR 16.00;
(2) the amount that would be recognized under 42 U.S.C. 1395l(h) for tests performed for a
person with Medicare Part B benefits; or
(3) the usual and customary fee.
(B) Usual and Customary Fee. The term usual and customary means the lowest fee charged by
a hospital outpatient department laboratory for any laboratory service (including both individual
and profile tests) specified in the hospital outpatient department's charge book or by such
hospital, with the exception of a fee offered for a bulk purchase. (A bulk purchase is a single
purchase of a laboratory service (one or more tests) to be uniformly and concurrently performed
on a minimum of 40 specimens of the same type. A single purchase of various, non-uniform
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laboratory services, such as by a physician, is not considered a bulk purchase, regardless of the
number of specimens presented by such a purchaser to the hospital outpatient department
laboratory.)
(C) Profile or Panel Tests.
(1) A profile or panel test is any group of tests, whether performed manually, automatedly, or
semiautomatedly, that is ordered for a specified recipient on a specified day and has at least one
of the following characteristics.
(a) The group of tests is designated as a profile or panel by the hospital outpatient department
laboratory performing the tests.
(b) The group of tests is performed by the hospital outpatient department laboratory at a usual
and customary fee that is lower than the sum of that hospital outpatient department laboratory's
usual and customary fees for the individual tests in that group.
(2) In no event shall a hospital outpatient department laboratory bill or be paid separately for
each of the tests included in a profile test when a profile test has either been performed by that
hospital outpatient department laboratory or requested by an authorized person.
410.457: Laboratory Services: Request for Services
The hospital outpatient department must have either a written requisition or a written order for
the laboratory service signed by an authorized prescriber (that is, a licensed physician or dentist,
or a registered nurse practitioner) before performing the service. A written requisition signed
only by an unauthorized prescriber is not acceptable. Any failure or inability to make the
authorized requisition or order available to the Division for review will be sufficient reason to
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deny or recover payment for all services based on that requisition or order. The hospital
outpatient department may send disclosures concerning the test only to the prescriber, to the
referring laboratory, if applicable, to the Division, and, at the written request of the prescriber, to
the recipient.
410.458: Laboratory Services: Recordkeeping Requirements
In addition to meeting the recordkeeping requirements specified in 130 CMR 410.409, the
hospital outpatient department must keep a suitable record of each specimen and laboratory test
result for at least six years from the date on which the results were reported to the prescriber.
Such a record must contain the following information:
(A) the name and any other means of identification of the person from whom the specimen was
taken;
(B) the name of the prescriber or laboratory that submitted the specimen;
(C) the authorized requisition or order, or both;
(D) the location where the specimen was taken, if other than the hospital outpatient department;
(E) the date on which the specimen was collected by the prescriber or laboratory;
(F) the date on which the specimen was received in the laboratory;
(G) the condition of unsatisfactory specimens when received (for example, broken, leaked,
hemolyzed, turbid, or insufficient sample size);
(H) the date on which the test was performed;
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(I) the test name and the results of the test, or the cross reference to results and the date of
reporting; and
(J) the name and address of the laboratory to which the specimen was referred, if applicable.
410.459: Laboratory Services: Specimen Referral
A hospital outpatient department may refer a specimen to an independent laboratory that is
eligible to participate in the Medical Assistance Program, or to another hospital laboratory that is
eligible to participate in the Medical Assistance Program. To be eligible, a hospital laboratory
must be in a hospital that is licensed by the Massachusetts Department of Public Health and that
is an approved Medicare provider. The referring hospital outpatient department laboratory must
inform the prescriber of the name and address of the testing laboratory. The testing laboratory
must inform the referring hospital outpatient department laboratory of the results of the test.
Only the referring laboratory is authorized to bill the Division.

Source: Commonwealth of Massachusetts Provider Manual Series

